journal
https://read.qxmd.com/read/38684821/clonal-hematopoiesis-derived-therapy-related-myeloid-neoplasms-after-autologous-hematopoietic-stem-cell-transplant-for-lymphoid-and-non-lymphoid-disorders
#21
JOURNAL ARTICLE
Hussein Awada, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Teodora Kuzmanovic, Hassan Awada, Zheng Jin Tu, James R Cook, Brian J Bolwell, Ronald Sobecks, Matt Kalaycio, David Bosler, Jaroslaw P Maciejewski
Therapy-related myeloid neoplasms (tMN) are complications of cytotoxic therapies. Risk of tMN is high in recipients of autologous hematopoietic stem cell transplantation (aHSCT). Acquisition of genomic mutations represents a key pathogenic driver but the origins, timing and dynamics, particularly in the context of preexisting or emergent clonal hematopoiesis (CH), have not been sufficiently clarified. We studied a cohort of 1507 patients undergoing aHSCT and a cohort of 263 patients who developed tMN without aHSCT to determine clinico-molecular features unique to post-aHSCT tMN...
April 29, 2024: Leukemia
https://read.qxmd.com/read/38678093/the-addition-of-bortezomib-to-rituximab-high-dose-cytarabine-and-dexamethasone-in-relapsed-or-refractory-mantle-cell-lymphoma-a-randomized-open-label-phase-iii-trial-of-the-european-mantle-cell-lymphoma-network
#22
JOURNAL ARTICLE
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety...
April 27, 2024: Leukemia
https://read.qxmd.com/read/38678092/the-kmt2a-mll-consensus-gene-structure-a-comprehensive-update-for-research-and-diagnostic-implications
#23
JOURNAL ARTICLE
C Meyer, P Larghero, B A Lopes, R Marschalek
No abstract text is available yet for this article.
April 27, 2024: Leukemia
https://read.qxmd.com/read/38664547/immunogenetics-in-hematopathology-and-hematology-why-a-common-language-is-important
#24
REVIEW
Kostas Stamatopoulos, Elspeth Bruford, Elias Campo, Marie-Paule Lefranc
No abstract text is available yet for this article.
April 25, 2024: Leukemia
https://read.qxmd.com/read/38643304/8-cl-ado-and-8-nh-2-ado-synergize-with-venetoclax-to-target-the-methionine-mat2a-sam-axis-in-acute-myeloid-leukemia
#25
JOURNAL ARTICLE
Jiamin Guo, Ralf Buettner, Li Du, Zhenlong Li, Wei Liu, Rui Su, Zhenhua Chen, Yuan Che, Yi Zhang, Rui Ma, Le Xuan Truong Nguyen, Roger E Moore, Pathak Khyatiben, Min-Hsuan Chen, Pirrotte Patrick, Xiwei Wu, Guido Marcucci, Lili Wang, David Horne, Jianjun Chen, Yanzhong Yang, Steven T Rosen
Targeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising therapeutical strategy. In particular, the cysteine and methionine metabolism pathway (C/M) is significantly altered in AML cells compared to healthy blood cells. Moreover, methionine has been identified as one of the dominant amino acid dependencies of AML cells. Through RNA-seq, we found that the two nucleoside analogs 8-chloro-adenosine (8CA) and 8-amino-adenosine (8AA) significantly suppress the C/M pathway in AML cells, and methionine-adenosyltransferase-2A (MAT2A) is one of most significantly downregulated genes...
April 20, 2024: Leukemia
https://read.qxmd.com/read/38637690/measurable-residual-disease-mrd-testing-in-haematological-and-solid-cancers
#26
REVIEW
Junren Chen, Robert Peter Gale, Yu Hu, Wen Yan, Tiantian Wang, Wei Zhang
No abstract text is available yet for this article.
April 18, 2024: Leukemia
https://read.qxmd.com/read/38637689/dynamics-of-clonal-hematopoiesis-under-dna-damaging-treatment-in-patients-with-ovarian-cancer
#27
JOURNAL ARTICLE
Christopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, Natalia Estrada, Friederike Christen, Ute Martha Moll, Robert Zeillinger, Wolfgang Daniel Schmitt, Jalid Sehouli, Hagen Kulbe, Maximilian Fleischmann, Isabelle Ray-Coquard, Alain Zeimet, Francesco Raspagliesi, Claudio Zamagni, Ignace Vergote, Domenica Lorusso, Nicole Concin, Lars Bullinger, Elena Ioana Braicu, Frederik Damm
Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs). Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein 90 inhibitor (HSP90i) treatment within the phase II EUDARIO trial using error-corrected sequencing of 72 genes...
April 18, 2024: Leukemia
https://read.qxmd.com/read/38632314/kras-g12-mutations-as-adverse-prognostic-factors-in-kmt2a-rearranged-acute-myeloid-leukemia
#28
JOURNAL ARTICLE
Shinju Iyoda, Kenichi Yoshida, Kota Shoji, Nana Ito, Miu Tanaka, Yasuhito Nannya, Genki Yamato, Shinichi Tsujimoto, Norio Shiba, Yasuhide Hayashi, Yusuke Shiozawa, Yuichi Shiraishi, Kenichi Chiba, Ai Okada, Hiroko Tanaka, Satoru Miyano, Yuhki Koga, Hiroaki Goto, Hiroshi Moritake, Kiminori Terui, Etsuro Ito, Nobutaka Kiyokawa, Daisuke Tomizawa, Takashi Taga, Akio Tawa, Junko Takita, Momoko Nishikori, Souichi Adachi, Seishi Ogawa, Hidemasa Matsuo
No abstract text is available yet for this article.
April 18, 2024: Leukemia
https://read.qxmd.com/read/38632316/mutations-in-the-splicing-factor-sf3b1-are-linked-to-frequent-emergence-of-hla-dr-low-neg-monocytes-in-lower-risk-myelodysplastic-neoplasms
#29
JOURNAL ARTICLE
Susann Winter, Marie Schneider, Uta Oelschlaegel, Giulia Maggioni, Elena Riva, Marco Gabriele Raddi, Sara Bencini, Benedetta Peruzzi, Desmond Choy, Rita Antunes Dos Reis, Esther Güse, Christopher Lischer, Julio Vera, Jessica A Timms, Nicolas Sompairac, Katja Sockel, Antonella Poloni, Antje Tunger, Matteo Giovanni Della Porta, Valeria Santini, Marc Schmitz, Uwe Platzbecker, Shahram Kordasti
No abstract text is available yet for this article.
April 17, 2024: Leukemia
https://read.qxmd.com/read/38632315/prophylactic-donor-derived-cd19-car-t-cell-infusion-for-preventing-relapse-in-high-risk-b-all-after-allogeneic-hematopoietic-stem-cell-transplantation
#30
JOURNAL ARTICLE
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
No abstract text is available yet for this article.
April 17, 2024: Leukemia
https://read.qxmd.com/read/38627586/autophagy-degrades-immunogenic-endogenous-retroelements-induced-by-5-azacytidine-in-acute-myeloid-leukemia
#31
JOURNAL ARTICLE
Nandita Noronha, Chantal Durette, Maxime Cahuzac, Bianca E Silva, Justine Courtois, Juliette Humeau, Allan Sauvat, Marie-Pierre Hardy, Krystel Vincent, Jean-Philippe Laverdure, Joël Lanoix, Frédéric Baron, Pierre Thibault, Claude Perreault, Gregory Ehx
The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherapy. The effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, evidence supporting higher ERE MAPs presentation after AZA treatment is lacking. Therefore, using proteogenomics, we examined the impact of AZA on the repertoire of MAPs and their source transcripts...
April 16, 2024: Leukemia
https://read.qxmd.com/read/38622290/correction-to-histone-deacetylase-hdac-inhibitor-acy241-enhances-anti-tumor-activities-of-antigen-specific-central-memory-cytotoxic-t-lymphocytes-against-multiple-myeloma-and-solid-tumors
#32
Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Yan Song, Paul Richardson, Noopur Raje, Nikhil C Munshi, Kenneth C Anderson
No abstract text is available yet for this article.
April 15, 2024: Leukemia
https://read.qxmd.com/read/38615117/combination-therapies-with-ponatinib-and-asciminib-in-a-preclinical-model-of-chronic-myeloid-leukemia-blast-crisis-with-compound-mutations
#33
JOURNAL ARTICLE
Nikola Curik, Adam Laznicka, Vaclava Polivkova, Jitka Krizkova, Eva Pokorna, Pavel Semerak, Pavla Suchankova, Pavel Burda, Andreas Hochhaus, Katerina Machova Polakova
No abstract text is available yet for this article.
April 13, 2024: Leukemia
https://read.qxmd.com/read/38609496/fluorescence-in-situ-hybridization-reveals-the-evolutionary-biology-of-minor-clone-of-gain-amp-1q-in-multiple-myeloma
#34
JOURNAL ARTICLE
Jian Cui, Yuntong Liu, Rui Lv, Wenqiang Yan, Jingyu Xu, Lingna Li, Chenxing Du, Tengteng Yu, Shuaishuai Zhang, Shuhui Deng, Weiwei Sui, Mu Hao, Shuhua Yi, Dehui Zou, Lugui Qiu, Yan Xu, Gang An
Growing evidence suggests that gain or amplification [gain/amp(1q)] accumulates during disease progression of multiple myeloma (MM). Previous investigations have indicated that small gain/amp(1q) subclones present at the time of diagnosis may evolve into dominant clones upon MM relapse. However, the influence of a minor clone of gain/amp(1q) on MM survival, as well as the correlation between different clonal sizes of gain/amp(1q) and the chromosomal instability (CIN) of MM, remains poorly understood. In this study, we analyzed fluorescence in situ hybridization (FISH) results of 998 newly diagnosed MM (NDMM) patients...
April 12, 2024: Leukemia
https://read.qxmd.com/read/38609495/metabolic-reprogramming-regulated-by-traf6-contributes-to-the-leukemia-progression
#35
JOURNAL ARTICLE
Shinichiro Matsui, Chihiro Ri, Lyndsey C Bolanos, Kwangmin Choi, Asuka Shibamiya, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Akihide Yoshimi, Koutaro Yokote, Daniel T Starczynowski, Emiko Sakaida, Tomoya Muto
TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Although altered TRAF6 expression is observed in human acute myeloid leukemia (AML), its role in the AML pathogenesis remains elusive. In this study, we showed that the loss of TRAF6 in AML cells significantly impairs leukemic function in vitro and in vivo, indicating its functional importance in AML subsets. Loss of TRAF6 induces metabolic alterations, such as changes in glycolysis, TCA cycle, and nucleic acid metabolism as well as impaired mitochondrial membrane potential and respiratory capacity...
April 12, 2024: Leukemia
https://read.qxmd.com/read/38600316/combination-p53-activation-and-bcl-x-l-bcl-2-inhibition-as-a-therapeutic-strategy-in-high-risk-and-relapsed-acute-lymphoblastic-leukemia
#36
JOURNAL ARTICLE
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL. Here, we demonstrate the potent antileukemic activity of the MDM2 antagonist idasanutlin in high-risk and relapsed ex vivo coculture models of TP53 wildtype ALL (n = 40). Insufficient clinical responses to monotherapy MDM2 inhibitors in other cancers prompted us to explore optimal drugs for combination therapy...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38600315/management-of-isocitrate-dehydrogenase-1-2-mutated-acute-myeloid-leukemia
#37
REVIEW
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has broadened our understanding of the heterogeneous molecular basis of the disease. Since genetic sequencing has become a standard practice, several driver mutations have been identified. Accordingly, novel targeted therapeutic agents have been developed and are now approved for the treatment of subsets of patients that carry mutations in FLT3, IDH1, and IDH2 [1, 2]. The emergence of these novel agents in AML offers patients a new modality of therapy, and shifts treatment paradigms toward individualized medicine...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38600314/genome-wide-dna-methylation-analysis-of-blastic-plasmacytoid-dendritic-cell-neoplasm-identifies-distinct-molecular-features
#38
JOURNAL ARTICLE
Axel Künstner, Julian Schwarting, Hanno M Witte, Pengwei Xing, Veronica Bernard, Stephanie Stölting, Philipp Lohneis, Florian Janke, Maede Salehi, Xingqi Chen, Kathrin Kusch, Holger Sültmann, Emil Chteinberg, Anja Fischer, Reiner Siebert, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred C Feller, Niklas Gebauer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients supplemented by WES and RNA-seq as well as ATAC-seq on selected cases. We determined the BPDCN DNA methylation profile and observed a dramatic loss of DNA methylation during malignant transformation from early and mature DCs towards BPDCN...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38594348/treatment-patterns-for-al-amyloidosis-after-frontline-daratumumab-bortezomib-cyclophosphamide-and-dexamethasone-treatment-failures
#39
JOURNAL ARTICLE
Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Joselle Cook, David Dingli, Nelson Leung, Yi Lin, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Robert A Kyle, S Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri
No abstract text is available yet for this article.
April 9, 2024: Leukemia
https://read.qxmd.com/read/38580835/pre-frailty-after-blood-or-marrow-transplantation-and-the-risk-of-subsequent-mortality
#40
JOURNAL ARTICLE
Nora Balas, Joshua S Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, F Lennie Wong, Ravi Bhatia, Stephen J Forman, Saro H Armenian, Daniel J Weisdorf, Smita Bhatia
We examined the prevalence, risk factors, and association between pre-frailty and subsequent mortality after blood or marrow transplantation (BMT). Study participants were drawn from the BMT Survivor Study (BMTSS) and included 3346 individuals who underwent BMT between 1974 and 2014 at one of three transplant centers and survived ≥2 years post-BMT. Participants completed the BMTSS survey at a median of 9 years from BMT and were followed for subsequent mortality for a median of 5 years after survey completion...
April 5, 2024: Leukemia
journal
journal
20191
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.